✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Recovery · Peptide Reference

TB-500

Released: Last reviewed:

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Recovery Evidence grade: C Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
Synthetic peptide (Thymosin Beta-4 fragment)
Half-life
~2 hours after SC injection
Pharmacy pathway
See the dated FDA status notice above
Sports-ban status
WADA prohibited (S0 — Non-Approved Substances)
Common stack
BPC-157 ("Wolverine stack")
Common dose
2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance
Evidence grade
C (animal data; veterinary use in racehorses)
FDA status
Not FDA-approved (compounded)

Mechanism of action

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Standard dosing

Typical clinical use: 2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. TB-500 requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded). FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.

U.S. telehealth providers prescribing TB-500

The most commonly cited U.S. telehealth providers for TB-500 are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.

Trade-offs to know

TB-500 carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.

Related peptides in the recovery category

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

References

  1. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669. PMID: 17276433
  2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294
  3. Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.